Oct. Three, 2017 — Humira as soon as once more was the top-selling drug in america in 2016, incomes producer AbbVie greater than $13.6 billion in gross sales, in keeping with the newest report from QuintilesIMS Institute, which tracks drug spending and prescriptions yearly.
Spending on the drug, an anti-inflammatory, has tripled from $four.5 billion in 2012. It’s the fifth straight 12 months Humira topped the record of all drug gross sales.
Levothyroxine, for thyroid circumstances, was essentially the most generally prescribed drug, because it has been for every of the 5 years, with 123 million prescriptions in 2016.
The overall variety of all prescriptions disbursed in 2016 hit four.four billion, up 1.9% from 2015, on par with will increase seen in earlier years.
“Notably,” the authors of the report say, “persistent prescriptions with Three-month period have elevated dramatically within the final 2 years, and prescriptions grew by Three.Three% when adjusting for prescription measurement.”
Use of ache medicines, each narcotic and nonnarcotic, was down 1% as restrictions on prescribing and distributing have turn into extra frequent, in keeping with the report.
Within the report, authors Murray Aitken, govt director of the QuintilesIMS Institute, and Michael Kleinrock, analysis director, write that bill spending on medicines — the quantity pharmacy or hospital clients paid distributors — in 2016 grew extra slowly than within the earlier 12 months.
Spending grew by four.eight% in 2016, slowing considerably from eight.9% in 2015.
The report says that was largely attributable to smaller worth will increase for name-brand merchandise, fewer new merchandise, and decrease spending on hepatitis C therapies in 2016.
The report estimates that 226,000 new sufferers have been handled with hepatitis C medicines in 2016, down by 23,000 from the 12 months earlier than. The medication are probably curing 13% to 22% of the three million to five million contaminated sufferers in america, the authors write.
The report predicts spending will proceed to minimize within the subsequent 5 years.
“The outlook for medication spending by way of 2021 is for mid-single digit development pushed by additional clusters of progressive therapies, offset by a rising affect from manufacturers going through generic or biosimilar competitors,” the authors write.
|Humira (adalimumab; made by AbbVie)||four.5||13.6|
|Harvoni (ledipasvir and sofosbuvir; made by Gilead)||zero.zero||10.zero|
|Enbrel (etanercept; made by Amgen)||four.2||7.four|
|Lantus Solostar (insulin glargine injection; made by Sanofi)||2.Three||5.7|
|Remicade (infliximab; made by Janssen Biotech)||Three.eight||5.Three|
|Januvia (sitagliptin; made by Merck)||2.6||four.eight|
|Advair Diskus (fluticasone/salmeterol; made by GlaxoSmithKline)||four.6||four.7|
|Lyrica (pregabalin; made by Pfizer)||1.9||four.four|
|Crestor (rosuvastatin; made by AstraZeneca)||four.eight||four.2|
|Neulasta (pegfilgrastim; made by Amgen)||Three.four||four.2|
|Complete U.S. market||317.eight||450.zero|